Lockheed Martin Secures $92.8M AEGIS Sustainment Contract from U.S. Navy 
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026 
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 
ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China 
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts 
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation 
Boeing Secures Major $2.7 Billion U.S. Military Contract for Apache Helicopter Support 
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares 
Target Stock Rallies as Activist Interest Sparks Hopes for Strategic Change 
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel 
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 
Google Accelerates AI Infrastructure With Ironwood TPU Expansion in 2026 
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 
ROCKVILLE, Md., March 06, 2017 -- Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, announced that it has entered into a settlement agreement with Zydus Pharmaceutical (USA), Inc. and Cadila Healthcare Limited (collectively, “Zydus”) involving the ongoing patent litigation regarding Zydus’ Abbreviated New Drug Application (ANDA) seeking approval to market generic versions of Supernus’ Trokendi XR® (extended-release topiramate) capsules. The settlement agreement permits Zydus to begin selling a generic version of Trokendi XR® on January 1, 2023, or earlier under certain circumstances. The agreement will be submitted to the applicable governmental agencies.
Supernus intends to continue its vigorous enforcement of its patent rights for Trokendi XR®. Patent protection for Trokendi XR® expires no earlier than 2027.
Supernus is represented by attorneys from Haug Partners LLP and its corporate counsel, Saul Ewing LLP.
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company has two marketed products for epilepsy, Oxtellar XR® (extended-release oxcarbazepine) and Trokendi XR® (extended-release topiramate). The Company is also developing several product candidates to address large market opportunities in psychiatry, including SPN-810 for the treatment of Impulsive Aggression in ADHD patients and SPN-812 for the treatment of ADHD.
Forward Looking Statements
This press release contains forward-looking statements regarding the Company’s ability to defend and enforce its intellectual property rights covering Trokendi XR®. Actual results may differ materially from those in these forward-looking statements as a result of various factors, including, but not limited to, the ability of Supernus to finance potential litigation and to prevail in any such proceeding to successfully defend its intellectual property rights. For a further description of these and other risks facing the Company, please see the risk factors described in the Company’s 2015 Annual Report Form 10-K/A that was filed with the United States Securities and Exchange Commission on January 20, 2017 under the caption “Risk Factors”. Forward-looking statements speak only as of the date of this press release, and the Company undertakes no obligation to update or revise these statements, except as may be required by law.
Contact: Jack A. Khattar, President and CEO Gregory S. Patrick, Vice President and CFO Supernus Pharmaceuticals, Inc. 301-838-2591 Or Investor Contact: Peter Vozzo Westwicke Partners Office: (443) 213-0505 Mobile: (443) 377-4767 Email: [email protected]
